Drug Trial Radar · NCT06564194
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
75
Actual
Start
Sep 25, 2024
Primary completion
Dec 12, 2024
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Immorna Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Tigermed Consulting Co., Ltd
- First posted
- Aug 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the safety, reactogenicity and immunogenicity of an mRNA-based vaccine, JCXH-108, the prevention of Respiratory Syncytial Virus (RSV) infection and diseases. Participants will be randomized to receive either JCXH-108 or placebo.
Conditions
- Respiratory Syncytial Virus (RSV)
- Infectious Disease
Interventions
JCXH-108Biological
IM injection
PlaceboOther
IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAE FrequencyTime frame: Day 1 - Day 180 (6 Months)
- Injection site reactionTime frame: Day 1 - Day 30
- Solicited systemic reaction frequencyTime frame: Day 1 - Day 30
- AE frequencyTime frame: Day 1 -Day 30
- Medically attended AE frequencyTime frame: Day 1 - Day 180 (6 Months)
- Potential immune-mediated adverse events frequencyTime frame: Day 1 - Day 180 (6 Months)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Health Awareness
Jupiter, Florida
DelRicht - New Orleans
New Orleans, Louisiana
Sundance Clinical Research
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.